WHOPAR part 5 Suppliers submission of the SRA approved text

Similar documents
Artesunate 60 mg for injection WHOPAR part 5 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 LABELLING

Artesunate 120mg powder for injection (Guilin Pharmaceutical Co., Ltd), MA90 LABELLING. Page 1 of 6

JSC «Olainfarm», Latvia PAS-Na 5.52 g Powder for oral solutions

Artemether 20mg/lumefantrine 120mg WHOPAR part 5 12/2011 Dispersible tablets (Novartis Pharma AG), MA069 LABELLING. Page 1 of 6

Sulfamethoxazole/Trimethoprim 400mg/80mg Tablets (Micro Labs Ltd), HA598. WHOPAR part 5 July 2017 LABELLING

Artesunate/amodiaquine 100/270 mg WHOPAR part 5 03/2009, version 1.0 (Sanofi-Aventis) MA058 LABELING

Lamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX III LABELLING AND PACKAGE LEAFLET

Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dopamine 40 mg/ml Sterile Concentrate

Package leaflet: Information for the user. multibic potassium-free solution for haemodialysis/haemofiltration

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Lidocaine Hydrochloride 1% w/v Solution for Injection Lidocaine Hydrochloride

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

PART 1.B SPC, LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Ventolin Injection 500 micrograms/ml salbutamol sulfate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/17

2. What you need to know before you use Compound Sodium Lactate

Package leaflet: Information for the user. Carmellose sodium

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

Package leaflet: Information for the user

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Chirocaine mg/ml or 1.25 mg/ml solution for infusion For epidural use only.

Package leaflet: Information for the user. Tobramycin 40 mg/ml Solution for Injection tobramycin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Ondansetron] 2 mg/ml, Solution for injection/infusion Ondansetron

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml Solution for Injection/Infusion Cisatracurium 5 mg/ml Solution for Injection/Infusion

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate

PART 1 B SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

1. What Octostim Nasal Spray is and what it is used for

Health Products Regulatory Authority

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. PolyVar Yellow. Summary of Product Characteristics (SPC)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

Package leaflet: Information for the user. Ondansetron 4mg/5ml Syrup (ondansetron as ondansetron hydrochloride dihydrate)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

2. What you need to know before Marcain Polyamp Steripack is given to you

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package Leaflet: Information for the user. LUMIGAN 0.3 mg/ml, eye drops, solution, in single-dose container Bimatoprost

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

Package leaflet: Information for the patient. Selenium 10 micrograms/ml concentrate for solution for infusion. Sodium selenite

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

PACKAGE LEAFLET: INFORMATION FOR THE USER

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8, 10/2012] ANNEX I SUMMARY OF PROPOSED PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ENCEFAL-VAC SUMMARY OF PRODUCT CHARACTERISTICS

Patient Information Leaflet: Information for users

Package leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

PACKAGE LEAFLET: INFORMATION FOR THE USER. Calcium Folinate 10 mg/ml Injection

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )

Package leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine

Package leaflet: Information for the user. Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER. Nutriflex plus Solution for Infusion Amino acids / Glucose / Electrolytes

Transcription:

PARTICULARS TO APPEAR ON THE OUTER PACKAGING ΒΟΧ x 1 plastic ampoule x 2ml [4ml] 1. NAME OF THE MEDICINAL PRODUCT Ζophralen Ondansetron 2. STATEMENT OF ACTIVE SUBSTANCE(S) Each 2ml [4ml] plastic ampoule contains 4mg [8mg] of ondansetron (as hydrochloride dihydrate) 3. LIST OF EXCIPIENTS Citric acid monohydrate, sodium citrate dihydrate, sodium chloride and water for injections. 4. PHARMACEUTICAL FORM AND CONTENTS Solution for Injection 1 x 2ml [4ml] plastic ampoule 5. METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous or intramuscular use. For single use. Discard any unused portion. Read the package leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY 8. EXPIRY DATE From a microbiological point of view, unless the method of opening or dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. 9. SPECIAL STORAGE CONDITIONS 1

Store below 25ºC. Store in the original package in order to protect from light. 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER DEMO S.A. Pharmaceutical Industry 21 st km National Road Athens Lamia, 145 68 Krioneri Attica, Greece Tel.: +30 (210) 81 61 802 Fax: +30 (210) 81 61 587 12. MARKETING AUTHORISATION NUMBER(S) 4 mg/2 ml: 40893/09/19-02-2010 [8 mg/4 ml: 40895/09/19-02-2010] 13. BATCH NUMBER 14. GENERAL CLASSIFICATION FOR SUPPLY By limited medicinal prescription: For hospital use only 15. INSTRUCTIONS ON USE 16. INFORMATION IN BRAILLE Not applicable 2

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS plastic ampoule of 2ml [4ml] 1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Ζophralen 2. METHOD OF ADMINISTRATION For intravenous or intramuscular use 3. EXPIRY DATE 4. BATCH NUMBER LOT: XXXΧ 5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 4 mg/2 ml [8 mg/4 ml] 6. OTHER 3

PARTICULARS TO APPEAR ON THE OUTER PACKAGING ΒΟΧ x 1 glass ampoule x 2ml [4ml] 1. NAME OF THE MEDICINAL PRODUCT Ζophralen Ondansetron 2. STATEMENT OF ACTIVE SUBSTANCE(S) Each 2ml [4ml] glass ampoule contains 4mg [8mg] of ondansetron (as hydrochloride dihydrate) 3. LIST OF EXCIPIENTS Citric acid monohydrate, sodium citrate dihydrate, sodium chloride and water for injections. 4. PHARMACEUTICAL FORM AND CONTENTS Solution for Injection 1 x 2ml [4ml] glass ampoule 5. METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous or intramuscular use. For single use. Discard any unused portion. Read the package leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY 8. EXPIRY DATE From a microbiological point of view, unless the method of opening or dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. 9. SPECIAL STORAGE CONDITIONS 4

Store below 25ºC. Store in the original package in order to protect from light. 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER DEMO S.A. Pharmaceutical Industry 21 st km National Road Athens Lamia, 145 68 Krioneri Attica, Greece Tel.: +30 (210) 81 61 802 Fax: +30 (210) 81 61 587 12. MARKETING AUTHORISATION NUMBER(S) 4 mg/2 ml: 40893/09/19-02-2010 [8 mg/4 ml: 40895/09/19-02-2010] 13. BATCH NUMBER 14. GENERAL CLASSIFICATION FOR SUPPLY By limited medicinal prescription: For hospital use only 15. INSTRUCTIONS ON USE 16. INFORMATION IN BRAILLE Not applicable 5

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS glass ampoule of 2ml [4ml] 1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Ζophralen 2. METHOD OF ADMINISTRATION For intravenous or intramuscular use 3. EXPIRY DATE 4. BATCH NUMBER LOT: XXXΧ 5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 4 mg/2 ml [8 mg/4 ml] 6. OTHER 6